Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics


Aldeyra Therapeutics, Inc. (ALDX): $3.10

0.34 (+12.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALDX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALDX Stock Price Chart Interactive Chart >

Price chart for ALDX

ALDX Price/Volume Stats

Current price $3.10 52-week high $13.18
Prev. close $2.76 52-week low $2.36
Day low $2.75 Volume 417,000
Day high $3.11 Avg. volume 865,974
50-day MA $3.71 Dividend yield N/A
200-day MA $5.85 Market Cap 180.73M

Aldeyra Therapeutics, Inc. (ALDX) Company Bio


Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.


ALDX Latest News Stream


Event/Time News Detail
Loading, please wait...

ALDX Latest Social Stream


Loading social stream, please wait...

View Full ALDX Social Stream

Latest ALDX News From Around the Web

Below are the latest news stories about Aldeyra Therapeutics Inc that investors may wish to consider to help them evaluate ALDX as an investment opportunity.

Palatin Technologies: A Diamond In The Rough

Palatin Technologies, Inc. (NYSE American: PTN) is a company which I have been following for a number of years, and like many other small biotech companies, the stock has been on somewhat of a roller coaster. When I first started looking into Palatin, the company had no approved drugs and...

Alexander Ebbinghouse on Seeking Alpha | February 23, 2022

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

No summary available.

Seeking Alpha | February 17, 2022

Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference

LEXINGTON, Mass., February 10, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 2022 Global Healthcare Conference.

Yahoo | February 10, 2022

Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model

LEXINGTON, Mass., February 01, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that results from the randomized, double-masked, vehicle-controlled, crossover Phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an investigational new drug, is a first-in-c

Yahoo | February 1, 2022

HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...

Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.

Yahoo | January 18, 2022

Read More 'ALDX' Stories Here

ALDX Price Returns

1-mo -15.07%
3-mo -24.02%
6-mo -56.70%
1-year -75.24%
3-year -56.21%
5-year -34.74%
YTD -22.50%
2021 -41.69%
2020 18.07%
2019 -30.00%
2018 22.06%
2017 27.10%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5265 seconds.